CTKB (Cytek Biosciences) Current Deferred Revenue: $31.2 Mil (As of Mar. 2026)


CTKB Cytek Biosciences Inc CTKB
71 GF Score
Price $4.48
GF Value $5.83
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Cytek Biosciences Current Deferred Revenue?

Cytek Biosciences CTKB -2.08% 71 Current Deferred Revenue is $31.2 Mil as of Mar. 2026. GuruFocus rates CTKB with a GF Score™ of 71/100 and a GF Value™ of $5.83 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Cytek Biosciences's current deferred revenue for the quarter that ended in Mar. 2026 was $31.2 Mil.

Cytek Biosciences Current Deferred Revenue Related Terms

Cytek Biosciences Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Cytek Biosciences's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cytek Biosciences Current Deferred Revenue Chart

Cytek Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial 8.10 14.54 24.13 26.61 29.57

Cytek Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.75 30.01 29.78 29.57 31.18
CTKB
71GF Score
Cytek Biosciences Inc CTKB
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $31.2 Mil mean?
Cytek Biosciences (CTKB) has a Current Deferred Revenue of $31.2 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Cytek Biosciences and its competitors.
Is Cytek Biosciences' Current Deferred Revenue too high?
Cytek Biosciences' current Current Deferred Revenue is $31.2 Mil. Overall, Cytek Biosciences has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cytek Biosciences' Current Deferred Revenue compare to CERS and NPCE?
Cytek Biosciences' Current Deferred Revenue of $31.2 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Devices & Instruments company?
A good Current Deferred Revenue depends on the Medical Devices & Instruments industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Cytek Biosciences and its competitors. Cytek Biosciences's current Current Deferred Revenue is $31.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytek Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Cytek Biosciences (CTKB) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.83, compared to a current price of $4.48 — trading 23.2% below its estimated fair value. The current Current Deferred Revenue is $31.2 Mil. Cytek Biosciences' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Cytek Biosciences (CTKB), the current Current Deferred Revenue is $31.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cytek Biosciences (CTKB) Overvalued in 2026?

Based on GuruFocus' analysis, Cytek Biosciences stock appears to be undervalued. The current stock price of $4.48 is trading 23.2% below its estimated GF Value™ of $5.83. GuruFocus considers Cytek Biosciences to be Modestly Undervalued.

Key valuation signals for CTKB:

  • Current Deferred Revenue: $31.2 Mil
  • GF Value™: $5.83 vs. price of $4.48 (23.2% below fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the CTKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cytek Biosciences Business Description

Other Exchanges 8EQ:Germany
Address 47215 Lakeview Boulevard, Fremont, CA, USA, 94538
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
71GF Score

Get the complete analysis for CTKB

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.48
Price
$5.83
GF Value